Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00810693




Registration number
NCT00810693
Ethics application status
Date submitted
17/12/2008
Date registered
18/12/2008
Date last updated
22/11/2023

Titles & IDs
Public title
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Scientific title
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Secondary ID [1] 0 0
2008-003482-68
Secondary ID [2] 0 0
12934
Universal Trial Number (UTN)
Trial acronym
PATENT-1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pulmonary Hypertension 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Cardiovascular 0 0 0 0
Hypertension

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Riociguat (Adempas, BAY63-2521)
Treatment: Drugs - Riociguat (Adempas, BAY63-2521)
Treatment: Drugs - Placebo

Experimental: Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT - Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 12 weeks

Experimental: Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT - Participants received Riociguat orally as a film-coated tablet up to 1.5mg three times daily (tid) (titration between 1.0 mg and 1.5 mg tid based on an individual dose titration (IDT) scheme) for 12 weeks

Placebo Comparator: Placebo - Participants received Placebo orally as a film-coated tablet three times daily (tid) for 12 weeks


Treatment: Drugs: Riociguat (Adempas, BAY63-2521)
BAY63-2521: 1mg tid - 2.5mg tid orally for 12 weeks

Treatment: Drugs: Riociguat (Adempas, BAY63-2521)
BAY63-2521: 1.5mg tid orally for 12 weeks

Treatment: Drugs: Placebo
Matching Placebo tid orally for 12 weeks
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 12
Timepoint [1] 0 0
Baseline and week 12
Secondary outcome [1] 0 0
Pulmonary Vascular Resistance (PVR) - Change From Baseline to Week 12
Timepoint [1] 0 0
Baseline and week 12
Secondary outcome [2] 0 0
N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) - Change From Baseline to Week 12
Timepoint [2] 0 0
Baseline and week 12
Secondary outcome [3] 0 0
World Health Organization (WHO) Functional Class - Change From Baseline to Week 12
Timepoint [3] 0 0
Baseline and week 12
Secondary outcome [4] 0 0
Percentage of Participants With Clinical Worsening
Timepoint [4] 0 0
At week 12
Secondary outcome [5] 0 0
Borg CR 10 Scale - Change From Baseline to Week 12
Timepoint [5] 0 0
Baseline and week 12
Secondary outcome [6] 0 0
EQ-5D Utility Score - Change From Baseline to Week 12
Timepoint [6] 0 0
Baseline and week 12
Secondary outcome [7] 0 0
Living With Pulmonary Hypertension (LPH) Questionnaire - Change From Baseline to Week 12
Timepoint [7] 0 0
Baseline and week 12

Eligibility
Key inclusion criteria
- Male and female patients with symptomatic PAH (Idiopathic, Familial, Associated PAH
due to connective tissue disease, congenital heart disease, portal hypertension with
liver cirrhosis, or due to anorexigen or amphetamine use)

- Treatment naive patients and patients pre-treated with an Endothelin Antagonist or a
Prostacyclinanalogue (except I.V.).
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- All types of pulmonary hypertension except subtypes of Venice Group I specified in the
inclusion criteria, severe COPD (chronic obstructive pulmonary disease), uncontrolled
arterial hypertension, left heart failure.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
17/12/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
14/05/2012
Sample size
Target
Accrual to date
Final
445
Recruitment in Australia
Recruitment state(s)
NSW,QLD,TAS,VIC
Recruitment hospital [1] 0 0
- Darlinghurst
Recruitment hospital [2] 0 0
- New Lambton Heights
Recruitment hospital [3] 0 0
- Auchenflower
Recruitment hospital [4] 0 0
- Herston
Recruitment hospital [5] 0 0
Royal Hobart Hospital - Hobart
Recruitment hospital [6] 0 0
- Prahran
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
2305 - New Lambton Heights
Recruitment postcode(s) [3] 0 0
4066 - Auchenflower
Recruitment postcode(s) [4] 0 0
4029 - Herston
Recruitment postcode(s) [5] 0 0
7000 - Hobart
Recruitment postcode(s) [6] 0 0
3181 - Prahran
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Kentucky
Country [5] 0 0
United States of America
State/province [5] 0 0
Massachusetts
Country [6] 0 0
United States of America
State/province [6] 0 0
Nebraska
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
Ohio
Country [9] 0 0
United States of America
State/province [9] 0 0
Rhode Island
Country [10] 0 0
United States of America
State/province [10] 0 0
Texas
Country [11] 0 0
Argentina
State/province [11] 0 0
Capital Federal
Country [12] 0 0
Austria
State/province [12] 0 0
Oberösterreich
Country [13] 0 0
Austria
State/province [13] 0 0
Innsbruck
Country [14] 0 0
Austria
State/province [14] 0 0
Wien
Country [15] 0 0
Belgium
State/province [15] 0 0
Bruxelles - Brussel
Country [16] 0 0
Belgium
State/province [16] 0 0
Leuven
Country [17] 0 0
Brazil
State/province [17] 0 0
Rio Grande Do Sul
Country [18] 0 0
Brazil
State/province [18] 0 0
Sao Paulo
Country [19] 0 0
Brazil
State/province [19] 0 0
Rio de Janeiro
Country [20] 0 0
Canada
State/province [20] 0 0
Alberta
Country [21] 0 0
Canada
State/province [21] 0 0
Ontario
Country [22] 0 0
Canada
State/province [22] 0 0
Quebec
Country [23] 0 0
China
State/province [23] 0 0
Guangdong
Country [24] 0 0
China
State/province [24] 0 0
Beijing
Country [25] 0 0
China
State/province [25] 0 0
Shanghai
Country [26] 0 0
Czechia
State/province [26] 0 0
Praha 2
Country [27] 0 0
Denmark
State/province [27] 0 0
Aarhus N
Country [28] 0 0
France
State/province [28] 0 0
Besancon
Country [29] 0 0
France
State/province [29] 0 0
Brest
Country [30] 0 0
France
State/province [30] 0 0
GRENOBLE Cedex 09
Country [31] 0 0
France
State/province [31] 0 0
Lille Cedex
Country [32] 0 0
France
State/province [32] 0 0
Montpellier
Country [33] 0 0
France
State/province [33] 0 0
Nice
Country [34] 0 0
France
State/province [34] 0 0
Pessac
Country [35] 0 0
France
State/province [35] 0 0
Rouen
Country [36] 0 0
Germany
State/province [36] 0 0
Baden-Württemberg
Country [37] 0 0
Germany
State/province [37] 0 0
Bayern
Country [38] 0 0
Germany
State/province [38] 0 0
Hessen
Country [39] 0 0
Germany
State/province [39] 0 0
Mecklenburg-Vorpommern
Country [40] 0 0
Germany
State/province [40] 0 0
Niedersachsen
Country [41] 0 0
Germany
State/province [41] 0 0
Nordrhein-Westfalen
Country [42] 0 0
Germany
State/province [42] 0 0
Saarland
Country [43] 0 0
Germany
State/province [43] 0 0
Sachsen
Country [44] 0 0
Greece
State/province [44] 0 0
Chaidari
Country [45] 0 0
Israel
State/province [45] 0 0
Petah Tikva
Country [46] 0 0
Italy
State/province [46] 0 0
Friuli-Venezia Giulia
Country [47] 0 0
Italy
State/province [47] 0 0
Lazio
Country [48] 0 0
Italy
State/province [48] 0 0
Lombardia
Country [49] 0 0
Italy
State/province [49] 0 0
Piemonte
Country [50] 0 0
Japan
State/province [50] 0 0
Aichi
Country [51] 0 0
Japan
State/province [51] 0 0
Fukui
Country [52] 0 0
Japan
State/province [52] 0 0
Hyogo
Country [53] 0 0
Japan
State/province [53] 0 0
Ibaraki
Country [54] 0 0
Japan
State/province [54] 0 0
Ishikawa
Country [55] 0 0
Japan
State/province [55] 0 0
Kanagawa
Country [56] 0 0
Japan
State/province [56] 0 0
Miyagi
Country [57] 0 0
Japan
State/province [57] 0 0
Okinawa
Country [58] 0 0
Japan
State/province [58] 0 0
Tokyo
Country [59] 0 0
Japan
State/province [59] 0 0
Hiroshima
Country [60] 0 0
Japan
State/province [60] 0 0
Okayama
Country [61] 0 0
Korea, Republic of
State/province [61] 0 0
Seoul Teugbyeolsi
Country [62] 0 0
Korea, Republic of
State/province [62] 0 0
Seoul
Country [63] 0 0
Mexico
State/province [63] 0 0
Jalisco
Country [64] 0 0
Mexico
State/province [64] 0 0
Nuevo Leon
Country [65] 0 0
Mexico
State/province [65] 0 0
Sinaloa
Country [66] 0 0
Mexico
State/province [66] 0 0
Mexico D.F.
Country [67] 0 0
Mexico
State/province [67] 0 0
Querétaro
Country [68] 0 0
New Zealand
State/province [68] 0 0
Christchurch
Country [69] 0 0
Poland
State/province [69] 0 0
Otwock
Country [70] 0 0
Portugal
State/province [70] 0 0
Coimbra
Country [71] 0 0
Portugal
State/province [71] 0 0
Lisboa
Country [72] 0 0
Portugal
State/province [72] 0 0
Porto
Country [73] 0 0
Russian Federation
State/province [73] 0 0
Moscow
Country [74] 0 0
Russian Federation
State/province [74] 0 0
St. Petersburg
Country [75] 0 0
Singapore
State/province [75] 0 0
Singapore
Country [76] 0 0
Spain
State/province [76] 0 0
Barcelona
Country [77] 0 0
Spain
State/province [77] 0 0
Sevilla
Country [78] 0 0
Sweden
State/province [78] 0 0
Linköping
Country [79] 0 0
Sweden
State/province [79] 0 0
Lund
Country [80] 0 0
Sweden
State/province [80] 0 0
Umeå
Country [81] 0 0
Switzerland
State/province [81] 0 0
Zürich
Country [82] 0 0
Taiwan
State/province [82] 0 0
Kaohsiung City
Country [83] 0 0
Taiwan
State/province [83] 0 0
Taipei
Country [84] 0 0
Thailand
State/province [84] 0 0
Bangkok
Country [85] 0 0
Thailand
State/province [85] 0 0
Chiang Mai
Country [86] 0 0
Turkey
State/province [86] 0 0
Ankara
Country [87] 0 0
Turkey
State/province [87] 0 0
Istanbul
Country [88] 0 0
Turkey
State/province [88] 0 0
Izmir
Country [89] 0 0
United Kingdom
State/province [89] 0 0
Cambridgeshire
Country [90] 0 0
United Kingdom
State/province [90] 0 0
West Dunbartonshire
Country [91] 0 0
United Kingdom
State/province [91] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Bayer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521
given orally for 12 weeks, in patients with symptomatic Pulmonary Arterial Hypertension
(PAH).
Trial website
https://clinicaltrials.gov/ct2/show/NCT00810693
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bayer Study Director
Address 0 0
Bayer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00810693